Works Cited
1. www.niaid.nih.gov/daids
2.
Kane, B.
2000. HIV vaccines: inch by
inch. Annals of Internal Medicine. 133:489-490.
3.
Dimitrov, D.S.
and C.C. Broder. 1997. HIV and membrane receptors. For www.AccessScience.com
4.
Prescott, L.M. et al. 1999. Microbiology 4th Ed. McGraw-Hill.
Boston.
5. Esparza, J. et al. 2000. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet. 355:2061-2066.
6. Thompson, R.C.A. 2000. Molecular epidemiology of infectious diseases. Oxford UP. New York.
7.
Stryer, L. 1995. Biochemistry 4th Ed. W.H. Freeman and Co. New York.
8.
Greene, W.C.
1991. Mechanisms of disease: The molecular biology of Human
Immunodeficiency Virus Type 1 infection.
New England Journal of Medicine. 324:308.
9.
Bouhdoud, L.P.
et al. 2000. T-cell receptor mediated anergy of a human
immunodeficiency virus (HIV) gp120 specific CD4 cytotoxic T-cell clone, induced
by a natural HIV type 1 variant peptide.
Journal of Virology. 74:2121-2128.
10. Rubenstein, A. et al. 1999. Immunologic responses of HIV-1 infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. Journal of AIDS. 22:467-476.
11.
Bartlett, J.G. 2001. The guide to living with HIV infection 5th
ed. Johns
Hopkins UP. Baltimore and London.
12.
Mitsuya, H. et
al. 1987. Strategies for antiviral
therapy in AIDS. Nature. 325: 773-778.
13.
Ward, D.E. ed. 1999. AmFar AIDS handbook: The complete guide to understanding HIV and
AIDS. W.W. Norton and Co. London.
14.
HIV Newsline. 1996
June. How protease inhibitors work.
15.
Markowitz,
M. 1997. Protease inhibitors: what
they are, how they work, when to use them.
IAPAC. Chicago.
16.
Bartlett, J.G. ed. 2000. The Johns Hopkins Hospital 2000-2001 guide to
medical care of patients with HIV infection.
8th Ed. Lipincott, Williams, and Wilkins. Philadelphia.
17.
Keiser, P.
2002. Role of Sequencing in Therapy Selection. Journal of Acquired Immune Deficiency Syndromes
and Human Retrovirology. 29: S19-S27.
18.
Casado, J.L.,
et al. 1998. Predictors of long term
response to protease inhibitor therapy in a cohort of HIV infected
patients. AIDS. 12: F135-F139.
19.
Michelet C. et
al. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone
in HIV infected patients. Antimicrobial
Agents and Chemotherapy. 45: 12:
3393-3402.
20.
Phillips, A.N. et al. 2001. Durability of HIV-1 viral suppression over
3.3 years with multi-drug antiretroviral therapy in previously drug naïve
individuals. AIDS. 15: 2379-2384.
21.
Lorenzi, P. et
al. 1997. Toxicity, efficacy, plasma
drug concentrations and protease mutations in patients with advanced HIV
infection treated with ritonavir plus saquinavir. AIDS. 11:
F95-F-99.
22.
Casado, J.L. et
al. 2002. Plasma drug levels,
genotypic resistance, and virological response to a
nelfinavir plus saquinavir containing regimen.
AIDS. 16: 47-52.
23.
Kodama, E.I. et al. 2001. 4’-Ethynyl nucleoside analogs: potent
inhibitors of multidrug-resistant HIV variants in
vitro. Antimicrobial Agents and
Chemotherapy. 45: 5: 1539-1546.
24.
Murray, P.R. et al. 1998. Medical Microbiology 3rd Ed. Mosby. St. Louis.
25.
Campiani, C. et
al. 1999. Pyrrolobenzoxazepinone
derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity
relationship studies and identification of more potent broad spectrum HIV-1 RT
inhibitors with antiviral activity. Journal
of Medical Chemistry. 42:
4462-4470.
26.
Tomlinson, J.A. et al. 1974. The inhibition of infection of cucumber
mosaic virus and influenza virus by extracts from Phytolacca
americana. Journal of General Virology. 22:225-232.
27.
Teltow, G.J. et
al. 1983. Inhibition of herpes simplex
virus DNA synthesis by pokeweed antiviral protein. Antimicrobial Agents and Chemotherapy. 23: 390.
28.
Kurinov, I.V.
et al. 1999.
X-ray crystallographic analysis of the structural basis for the
interactions of pokeweed antiviral protein with its active site inhibitor and
ribosomal RNA substrate analogs. Protein
Science. 8: 1765-1772.
29.
Uckun, F. et
al. 1999. Toxicity, biological activity,
and pharmacokinetics of TXU-pokeweed antiviral protein in chimpanzees and adult
patients infected with HIV. Pharmacology
and Experimental Therapeutics. 291:
1301-1307.
30.
Uckun, F. et
al. 1998. TXU-pokeweed antiviral
protein as a potent inhibitor of HIV.
Antimicrobial Agents and Chemotherapy.
42: 383-388.
31.
Schuster, D.I.
2000. Fullerene.
For www.AccessScience.com
32.
Borkow, G. et
al. 1999. The thiocarboxanilide
nonnucleoside inhibitor UC781 restores antiviral activity of AZT against
AZT-resistant HIV-1. Antimicrobial
Agents and Chemotherapy. 43:
259-263.
33.
Acosta, E.P.
2002. Pharmacokinetic enhancement of protease
inhibitors. Journal of Acquired Immune
Deficiency Syndromes and Human Retrovirology. 29: S11-S18.
34. Davey, R.T. Jr. et al. 2000. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy. A randomized controlled trial. Journal of the American Medical Association. 284:183-189.
35. Sandström, E. Nordic VAC-04 Study Group. 1999. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Lancet. 353:173542.
36.
Shen, X. and
R.F. Siciliano.
2000. Preventing AIDS but not
HIV-1 infection with a DNA vaccine.
Science. 290:463-465.
37.
Sabbaj, S.
NIAID AIDS Vaccine Evaluation Group.
2000. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. AIDS. 14:1365-1373.
38. Verrier, F., S. et al. 2000. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. Journal of Virology. 74:10025-10033.
39. Moss, R.B. et al. 2000. T-helper cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1 infected subjects vaccinated with HIV-1 immunogen (Remune). Clinical and Diagnostic Laboratory Immunology. 7:724-726.
40. Murphy, C.G. et al. 2000. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. Journal of Virology. 74:7745-7753.
41. Auerbach, J.D. et al. eds. 1994. AIDS and behavior. An integrated approach. National Academy Press. Washington D.C.
42.
Powderly, W.G. 2002.
Long-term exposure to lifelong therapies. Journal of Acquired Immune Deficiency
Syndromes and Human Retrovirology. 29:
S28-S40
43.
Bartlett,
J.A. 2002. Addressing the challenges of adherence. Journal of Acquired Immune Deficiency
Syndromes and Human Retrovirology. 29:
S2-S10.
44. Baldwin, J.D. and J.I. Baldwin. 1998. Behavior principles in everyday life. 3rd Ed. Prentice Hall. New Jersey.
45. Wenger, N. and A. Gifford. 1999. Patient characteristics and attitudes associated with antiretroviral adherence. 6th Conference on Retroviruses and Opportunistic Infections. Chicago.
46.
Bruhn, J.G. 1999.
Social and psychological aspects of care. Ch.15 in
Muma, R.D. et al. eds. HIV manual for healthcare professionals. 2nd Ed. Appleton and Lange. Stamford.
47.
Ortega,
M.A. 1999. Social worker assessment and
intervention. Ch.13 in Muma, R.D. et al. eds. HIV manual for healthcare professionals. 2nd Ed. Appleton and Lange. Stamford.
48. Comer, R.J. 1998. Abnormal Psychology 3rd Ed. W.H. Freeman and Co. New York.
49.
Markowitz, J.D. et
al. 1994. Treating depression in HIV-positive
patients. AIDS. 8:
403-412.
50. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. American Psychiatric Press. Washington D.C.
51. Avery, E.N. 1999. Psychiatric care. Ch.14 in Muma, R.D. et al. eds. HIV manual for healthcare professionals. 2nd Ed. Appleton and Lange. Stamford.
52.
Navia, B.A. et
al. 1986. The AIDS dementia complex, 1. Clinical
features. Annals of Neurology. 19:
517-524.
53.
Sewell, D.D.
et al. 1994. HIV associated psychosis: A longitudinal study of 20 cases. American Journal of Psychiatry. 151:
237-242.
54.
Tomb,
D. 1995. Psychiatry 5th Ed. Williams and Wilkins. Baltimore.
55.
Thomas,
M. 1999. An exploration of change: The influence of
combination therapies on PWA support groups.
Ch.3 in Shernoff, M. ed. AIDS and mental healthcare
practice. Clinical and policy
issues. The Haworth Press. New York.
56.
www.gmhc.org
57.
Gushue, G.V. 1997.
Beyond science: Miracles, miracle cures, and
AIDS-the role of the therapist. In Wicks, L.A. ed. Psychotherapy and AIDS:
The human dimension. Taylor and
Francis. Washington D.C.
58.
Mellors, M.P. et
al. 2001. Transcending the suffering of AIDS. Journal of Community Health Nursing. 18:
235-246.
59.
Coward,
D.D. 1996. Self transcendence: A resource for healing at
the end of life. Issues in Mental Health
Care Nursing. 17: 275-288.
60.
Kübler-Ross, E. 1969.
On death and dying.
Macmillan. New York.
61.
Shernoff, M. 1999.
Dying well: Counseling end-stage clients with AIDS. Ch.15 in Shernoff, M. ed.
AIDS and mental healthcare practice.
Clinical and policy issues. The
Haworth Press. New York.
62. Rabkin, J. et al. 1994. Good doctors, good patients: Partners in HIV treatment. NCN Publishers. New York.